Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Chapman JA, Nielsen TO, Ellis MJ, Bernard P, Chia S, Gelmon KA, Pritchard KI, Le Maitre A, Goss PE, Leung S, Shepherd LE, Bramwell VH. Chapman JA, et al. Among authors: bramwell vh. Breast Cancer Res. 2013;15(4):R71. doi: 10.1186/bcr3465. Breast Cancer Res. 2013. PMID: 23972025 Free PMC article. Clinical Trial.
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI. O'Malley FP, et al. Among authors: bramwell vh. Breast Cancer Res Treat. 2011 Jul;128(2):401-9. doi: 10.1007/s10549-011-1511-5. Epub 2011 Apr 26. Breast Cancer Res Treat. 2011. PMID: 21519837 Clinical Trial.
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials.
Hilton JF, Bouganim N, Dong B, Chapman JW, Arnaout A, O'Malley F, Gelmon KA, Yerushalmi R, Levine MN, Bramwell VH, Whelan TJ, Pritchard KI, Shepherd LE, Clemons M. Hilton JF, et al. Among authors: bramwell vh. Breast Cancer Res Treat. 2013 Nov;142(1):143-51. doi: 10.1007/s10549-013-2714-8. Epub 2013 Oct 11. Breast Cancer Res Treat. 2013. PMID: 24113743
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Yerushalmi R, et al. Among authors: bramwell vhc. Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152. Ann Oncol. 2017. PMID: 28379421 Free PMC article.
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. Chia SK, et al. Among authors: bramwell vh. Clin Cancer Res. 2012 Aug 15;18(16):4465-72. doi: 10.1158/1078-0432.CCR-12-0286. Epub 2012 Jun 18. Clin Cancer Res. 2012. PMID: 22711706 Free PMC article.
143 results